Logo
x

Search

Subscribe Now

 P-III

Bayer Submits NDA of Elinzanetant, Seeking Approval in the US for Vasomotor Symptoms Treatment

Bayer Submits NDA of Elinzanetant, Seeking Approval in the US for Vasomotor Symptoms Treatment

  • August 2, 2024
GSK Reports the US FDA’s Expanded Approval of Jemperli Plus Chemotherapy for Treating Endometrial Cancer

GSK Reports the US FDA’s Expanded Approval of Jemperli Plus Chemotherapy for Treating Endometrial Cancer

  • August 2, 2024
Eli Lilly Reports the P-III (SUMMIT) Trial Data of Tirzepatide to Treat Heart Failure with Preserved Ejection Fraction and Obesity

Eli Lilly Reports the P-III (SUMMIT) Trial Data of Tirzepatide to Treat Heart Failure with Preserved Ejection Fraction and Obesity

  • August 2, 2024
Innovent Reports the NMPA’s NDA Acceptance of Mazdutide to Treat Type 2 Diabetes

Innovent Reports the NMPA’s NDA Acceptance of Mazdutide to Treat Type 2 Diabetes

  • August 1, 2024
Johnson & Johnson’s Darzalex Faspro Quadruplet Combination Gains the US FDA’s Approval to Treat Multiple Myeloma (MM)

Johnson & Johnson’s Darzalex Faspro Quadruplet Combination Gains the US FDA’s Approval to Treat Multiple Myeloma (MM)

  • July 31, 2024
Roche’s Vabysmo (Faricimab) Receives the EC’s Approval to Treat Retinal Vein Occlusion (RVO)

Roche’s Vabysmo (Faricimab) Receives the EC’s Approval to Treat Retinal Vein Occlusion (RVO)

  • July 30, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.